Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size
Open Access
- 13 July 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Abstract
The elimination of the latent viral reservoir remains the main barrier in the quest for a cure for people with HIV (PWH). The administration of latency reversal agents (LRA) at antiretroviral treatment (ART) initiation could improve the effectiveness of strategies aimed at HIV remission. This study assessed the impact of maraviroc (MVC), an antiretroviral drug with HIV latency reversal properties, on the viral reservoir size when it is administered at ART initiation. We conducted a longitudinal observational study in PWH initiating ART with a regimen including (MVC-initiation, n = 12) or not including MVC (non-MVC-initiation, n = 22), or switching to an MVC-containing regimen after achieving an undetectable viral load (VL) (MVC-switch, n = 9). The HIV reservoir size was determined via Alu-LTR and Intact Proviral DNA Assay (IPDA) methods, and cell-associated HIV-RNA (ca-HIV-RNA) by nested-qPCR. Comparative analyses employed mixed multivariate linear models. After a median of 90 weeks, the MVC-initiation group showed a greater reduction in integrated and IPDA-total (7.1- and 4.0-fold, respectively), but not IPDA-intact, HIV-DNA reservoir compared to the non-MVC-initiation group. The reductions in integrated, IPDA-total, and IPDA-intact HIV-DNA levels in the MVC-initiation group were also greater compared to the MVC-switch group (from 5.4 to 13.8-fold). Moreover, no significant differences in the HIV transcriptional activity, assessed by ca-HIV-RNA levels or HIV-RNA/HIV-DNA ratios, were observed between the MVC-initiation and non-MVC-initiation groups. In conclusion, starting ART with a drug with HIV latency reversing activity at detectable VL phase may contribute to a greater reduction in the HIV-DNA reservoir. These findings could inform the design of future trials targeting HIV remission via a “kick and kill” strategy.Keywords
Funding Information
- Instituto de Salud Carlos III (PI23/01896, PI23/01896)
This publication has 45 references indexed in Scilit:
- HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trialJournal of Medical Virology, 2023
- The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic reviewJournal of Virus Eradication, 2023
- HIV persistence in subsets of CD4+ T cells: 50 shades of reservoirsSeminars in Immunology, 2020
- Establishment of latent HIV-1 reservoirs: what do we really know?Journal of Virus Eradication, 2019
- Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIVCell Host & Microbe, 2018
- Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensificationJournal of Virus Eradication, 2015
- Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trialThe Lancet Infectious Diseases, 2015
- Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutationsNature, 2015
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trialThe Lancet HIV, 2014
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsNature Medicine, 2010